HomeCompareCCMP vs PFE

CCMP vs PFE: Dividend Comparison 2026

CCMP yields 13.47% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCMP wins by $3353054.86M in total portfolio value
10 years
CCMP
CCMP
● Live price
13.47%
Share price
$173.69
Annual div
$23.40
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3353054.91M
Annual income
$3,305,915,027,308.01
Full CCMP calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CCMP vs PFE

📍 CCMP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCMPPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCMP + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCMP pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCMP
Annual income on $10K today (after 15% tax)
$1,145.14/yr
After 10yr DRIP, annual income (after tax)
$2,810,027,773,211.81/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, CCMP beats the other by $2,810,027,750,082.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCMP + PFE for your $10,000?

CCMP: 50%PFE: 50%
100% PFE50/50100% CCMP
Portfolio after 10yr
$1676527.48M
Annual income
$1,652,957,527,259.27/yr
Blended yield
98.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CCMP
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCMP buys
0
PFE buys
0
No recent congressional trades found for CCMP or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCMPPFE
Forward yield13.47%6.20%
Annual dividend / share$23.40$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$3353054.91M$51.1K
Annual income after 10y$3,305,915,027,308.01$27,210.54
Total dividends collected$3349892.52M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCMP vs PFE ($10,000, DRIP)

YearCCMP PortfolioCCMP Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$13,394$2,694.46$9,161$701.38+$4.2KCCMP
2$21,078$6,745.94$8,610$859.79+$12.5KCCMP
3$42,396$19,842.34$8,366$1,081.25+$34.0KCCMP
4$119,962$74,598.94$8,483$1,405.66+$111.5KCCMP
5$522,909$394,549.27$9,084$1,907.24+$513.8KCCMP
6$3,774,123$3,214,610.22$10,418$2,732.78+$3.76MCCMP
7$47,405,812$43,367,500.22$13,007$4,193.56+$47.39MCCMP
8$1,068,907,945$1,018,183,726.54$18,010$7,005.87+$1068.89MCCMP
9$44,055,961,799$42,912,230,297.28$28,216$12,979.89+$44055.93MCCMP
10$3,353,054,906,432$3,305,915,027,308.01$51,081$27,210.54+$3353054.86MCCMP

CCMP vs PFE: Complete Analysis 2026

CCMPStock

CMC Materials, Inc., together with its subsidiaries, provides consumable materials to semiconductor manufacturers, and pipeline and adjacent industry customers in North America, Asia, Europe, the Middle East, Africa, and South America. The company operates in two segments, Electronic Materials and Performance Materials. The Electronic Materials segment develops, produces, and sells chemical mechanical planarization (CMP) slurries for polishing various materials used in IC devices, including tungsten, dielectric materials, copper, tantalum, and aluminum; and various materials that are used in the production of disk substrates and magnetic heads for hard disk drives; and CMP pads, which are used in conjunction with slurries in the CMP process. This segment also offers sulfuric, phosphoric, nitric, and hydrofluoric acids, as well as ammonium hydroxide, hydrogen peroxide, isopropyl alcohol, other specialty organic solvents, and various blends of chemicals; and develops and manufactures consumable products for cleaning advanced probe cards and test sockets. The Performance Materials segment provides pipeline and industrial materials comprising polymer-based drag-reducing agents for crude oil transmission, valve greases, cleaners and sealants, and related services and equipment; and routine and emergency maintenance services, as well as training services. This segment also offers precision polishing and metrology systems for advanced optics applications; and magneto-rheological polishing fluids, consumables, and spare and replacement parts, as well as optical polishing services and other customer support services; and engages in the wood treatment business. The company was formerly known as Cabot Microelectronics Corporation and changed its name to CMC Materials, Inc. in October 2020. CMC Materials, Inc. was incorporated in 1999 and is headquartered in Aurora, Illinois.

Full CCMP Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CCMP vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCMP vs SCHDCCMP vs JEPICCMP vs OCCMP vs KOCCMP vs MAINCCMP vs JNJCCMP vs MRKCCMP vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.